Pfizer will evaluate the application of Xencor’s Xtend™ antibody half-life prolongation technology and XmAb® ADCC enhancing technology in several of its discovery projects. In addition, Pfizer has taken a commercial license to Xencor’s technology for one program.
Xencor will receive an up-front payment and is eligible to considerations based on the successful commercialization of products that incorporate the Xencor technology.
